Selumetinib, an Oral Anti-Neoplastic Drug, May Attenuate Cardiac Hypertrophy via Targeting the ERK Pathway

AIMS: Although extracellular-regulated kinases (ERK) are a well-known central mediator in cardiac hypertrophy, no clinically available ERK antagonist has been tested for preventing cardiac hypertrophy. Selumetinib is a novel oral MEK inhibitor that is currently under Phase II and Phase III clinical...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: Li, Chen, Chen, Zhongxiu, Yang, Hao, Luo, Fangbo, Chen, Lihong, Cai, Huawei, Li, Yajiao, You, Guiying, Long, Dan, Li, Shengfu, Zhang, Qiuping, Rao, Li
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2016
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4954659/
https://ncbi.nlm.nih.gov/pubmed/27438013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0159079
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados